The regulatory acceptance enables a team of gastroenterologists at Beth Israel Deaconess Medical Center to initiate a Phase II randomized, triple-blind, and placebo-controlled clinical trial to investigate the role of the gut microbiome in patients with Irritable Bowel Syndrome, as well as the impact of DS-01™ on both intestinal cells and metabolic output of the native intestinal microbial communities.
[Seed Health Inc. (PRNews]
6606345
{6606345:nan}
apa
50
1
154992
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/